Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potential

on MSN ago, source:

IN8bio Inc (NASDAQ:INAB) revealed new preclinical data from its non-signaling gamma-delta T cell-based Chimeric Antigen ...

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

6d ago, source:

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing ...

INAB: Initiating Coverage – Enhancing the Insurgents of the Immune System

1d ago, source:

INAB READ THE FULL INAB RESEARCH REPORT We are initiating coverage of IN8bio, Inc. (NASDAQ:INAB) with a valuation of $5.00 per share. This value is based on our estimates for a successful development ...

IN8bio Inc Ordinary Shares INAB

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

1mon ago, source: Business Insider

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth ...

Promising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR Platform

11d ago, source:

Uy Ear, an analyst from Mizuho Securities, maintained the Buy rating on IN8bio (INAB – Research Report). The associated price target ...

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

13d ago, source: Nasdaq

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new ...

IN8bio Stock (NASDAQ:INAB), Analyst Ratings, Price Targets, Predictions

1mon ago, source: Benzinga.com

There is no last upgrade for IN8bio.

IN8bio Inc.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

IN8bio Inc Ordinary Shares

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

13d ago, source: Stockhouse

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new preclinical ...

IN8bio, Inc: IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

13d ago, source:

Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced technology ...